Pfizer has announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company, Therachon Holding.
Under the terms of the transaction, Pfizer acquired the Switzerland-based biotech for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46. TA-46 is an investigational medicine for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism.
Pfizer intends for the early clinical development program for achondroplasia to augment its Rare Disease portfolio.
Read the press release
Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.